Lack of association between soluble CD40L and risk in a large cohort of patients with acute coronary syndrome in OPUS TIMI-16

Journal of Thrombosis and Thrombolysis

Volumn 26, Issue 2, 2008, Pages 79-84

  Olenchock, Benjamin A ^a,b   Wiviott, Stephen D ^b   Murphy, Sabina A ^b   Cannon, Christopher P ^b   Rifai, Nader ^c   Braunwald, Eugene ^b   Morrow, David A ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Acute coronary syndromes; Biomarkers; OPUS; Soluble CD40L; TIMI 16

Indexed keywords

CD40 LIGAND;

ACUTE CORONARY SYNDROME; ADULT; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR RISK; CASE CONTROL STUDY; COHORT ANALYSIS; CONTROLLED STUDY; DEATH; DISEASE ASSOCIATION; FEMALE; HEART FAILURE; HEART INFARCTION; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; RISK FACTOR;

ACUTE CORONARY SYNDROME; AGED; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CD40 LIGAND; COHORT STUDIES; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PREDICTIVE VALUE OF TESTS; RECURRENCE; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; UP-REGULATION;

EID: 56049105881     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11239-007-0156-z     Document Type: Article

References (22)

1. Hansson GK, Libby P (2006) The immune response in atherosclerosis: A double-edged sword. Nat Rev Immunol 6:508-519
2. Apple FS, Wu AH, Mair J et al (2005) Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome. Clin Chem 51:810-824
3. Mach F, Schonbeck U, Libby P (1998) CD40 signaling in vascular cells: A key role in atherosclerosis? Atherosclerosis 137(Suppl):S89-S95
4. Mach F, Schonbeck U, Sukhova GK et al (1997) Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: Implications for CD40-CD40 ligand signaling in atherosclerosis. Proc Natl Acad Sci USA 94:1931-1936
5. Henn V, Slupsky JR, Grafe M et al (1998) CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 391:591-594
6. Aukrust P, Muller F, Ueland T et al (1999) Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation 100:614-620
7. Kinlay S, Schwartz GG, Olsson AG et al (2004) Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study. Circulation 110:386-391
8. Heeschen C, Dimmeler S, Hamm CW et al (2003) Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 348:1104-1111
9. Varo N, de Lemos JA, Libby P et al (2003) Soluble CD40L: Risk prediction after acute coronary syndromes. Circulation 108:1049-1052
10. Schonbeck U, Varo N, Libby P, Buring J, Ridker PM (2001) Soluble CD40L and cardiovascular risk in women. Circulation 104:2266-2268
11. Bereczki D, Nagy E, Pal A, Magyar MT, Balla J (2003) Should soluble CD40 ligand be measured from serum or plasma samples? Arterioscler Thromb Vasc Biol 23:1129-1130; author reply 1130-1131
12. Ahn ER, Lander G, Jy W et al (2004) Differences of soluble CD40L in sera and plasma: Implications on CD40L assay as a marker of thrombotic risk. Thromb Res 114:143-148
13. Halldorsdottir AM, Stoker J, Porche-Sorbet R, Eby CS (2005) Soluble CD40 ligand measurement inaccuracies attributable to specimen type, processing time, and ELISA method. Clin Chem 51:1054-1057
14. Nannizzi-Alaimo L, Rubenstein MH, Alves VL, Leong GY, Phillips DR, Gold HK (2002) Cardiopulmonary bypass induces release of soluble CD40 ligand. Circulation 105:2849-2854
15. Thom J, Gilmore G, Yi Q, Hankey GJ, Eikelboom JW (2004) Measurement of soluble P-selectin and soluble CD40 ligand in serum and plasma. J Thromb Haemost 2:2067-2069
16. Weber M, Rabenau B, Stanisch M et al (2006) Influence of sample type and storage conditions on soluble CD40 ligand assessment. Clin Chem 52:888-891
17. Varo N, Nuzzo R, Natal C, Libby P, Schonbeck U (2006) Influence of pre-analytical and analytical factors on soluble CD40L measurements. Clin Sci (Lond) 111:341-347
18. Ivandic BT, Spanuth E, Haase D, Lestin HG, Katus HA (2007) Increased plasma concentrations of soluble CD40 ligand in acute coronary syndrome depend on in vitro platelet activation. Clin Chem 53:1231-1234
19. Cannon CP, McCabe CH, Wilcox RG et al (2000) Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial. Circulation 102:149-156
20. Morrow DA, de Lemos JA (2007) Benchmarks for the assessment of novel cardiovascular biomarkers. Circulation 115:949-952
21. Pearson TA, Mensah GA, Hong Y, Smith SC Jr (2004) CDC/AHA Workshop on markers of inflammation and cardiovascular disease: Application to clinical and public health practice: Overview. Circulation 110:e543-e544
22. Lip GY, Patel JV, Hughes E, Hart RG (2007) High-sensitivity C-reactive protein and soluble CD40 ligand as indices of inflammation and platelet activation in 880 patients with nonvalvular atrial fibrillation. Relationship to stroke risk factors, stroke risk stratification schema, and prognosis. Stroke